- Home
- ARHS vs SLDB Comparison
ARHS vs SLDB Comparison
Compare ARHS & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | SLDB |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.8M | 1.1B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ARHS | SLDB |
|---|---|---|
| Price | $9.35 | $9.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $10.78 | ★ $16.36 |
| AVG Volume (30 Days) | ★ 1.7M | 893.5K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $1,379,222,000.00 | $8,094,000.00 |
| Revenue This Year | $7.23 | N/A |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | $32.17 | ★ N/A |
| Revenue Growth | ★ 8.51 | N/A |
| 52 Week Low | $5.57 | $3.79 |
| 52 Week High | $12.19 | $11.45 |
Technical Indicators
Market Signals| Indicator | ARHS | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 56.37 |
| Support Level | $7.28 | $6.25 |
| Resistance Level | $11.39 | $11.45 |
| Average True Range (ATR) | 0.58 | 0.45 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 62.60 | 66.77 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.